Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

BRIP1 mutation	Prostate Cancer	BRIP1 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
BRIP1 mutation	Ovarian Cancer	BRIP1 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
BRIP1 mutation	Prostate Cancer	BRIP1 mutation	Prostate Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
BRIP1 mutation	Urothelial Cancer	BRIP1 mutation	Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
BRIP1 mutation	HER2 Negative Breast Cancer	BRIP1 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
BRIP1 mutation	Pancreatic Cancer	BRIP1 mutation	Pancreatic Cancer	nivolumab + ABT-888 Sensitive: C3 – Early Trials nivolumab + ABT-888 Sensitive : C3	nivolumab + ABT-888 Sensitive: C3 – Early Trials nivolumab + ABT-888 Sensitive : C3
BRIP1 mutation	Colon Cancer	BRIP1 mutation	Colon Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HR positive + BRIP1 amplification	HER2 Negative Breast Cancer	HR positive + BRIP1 amplification	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
BRIP1 overexpression	Biliary Tract Cancer	BRIP1 overexpression	Biliary Tract Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
BRIP1 L680fs*9	Pancreatic Cancer	BRIP1 L680fs*9	Pancreatic Cancer	nivolumab + ABT-888 Sensitive: C4 – Case Studies nivolumab + ABT-888 Sensitive : C4	nivolumab + ABT-888 Sensitive: C4 – Case Studies nivolumab + ABT-888 Sensitive : C4